Botulinum Toxin for Erectile Dysfunction

Status Completed

Clinical Trial Summary

To evaluate the safety and efficacy of intra-cavernosal Botulinum toxin injection as an alternative line of treatment in patients with erectile dysfunction - not responding to oral PDE5i - through cavernosal smooth muscle relaxation.

Clinical Trial Description

The initial Phase 1 study demonstrated safety and efficacy of Botulinum toxin type A in the treatment of Erectile dysfunction in a small randomized controlled trial of 24 men.

The investigators conduct a phase 2 trial to confirm the initial results in a larger group of men.70 males will be included in the study. The participants will be subjected for full history taking, general and genital examination. Penile duplex will be performed to assess a vascular etiology before the treatment and 2 weeks later. The patients will be randomized into a treatment group (35 patients) and a control group (35 patients).

All patients will sign an informed consent. The treatment group will be injected IC with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for color Doppler assessment, followed, next day by 50 units of BTX-A. The control group will be injected with the trimix solution during penile color Doppler assessment followed next day with a normal saline injection. The erection hardness score (EHS) will be assessed during the Doppler exam.

Procedure: At least 1 day after the penile color Doppler test, the patient is placed in the supine position flaccid and stretched penile length and girth would be measured from tip of the penis to the pubic bone will be done. A rubber band will be applied to the base of the penis. The skin will be prepped with alcohol swabs followed by the IC injection of 100 units of BTX-A. Direct pressure will be applied for 2 minutes. The rubber band will be removed after 15 minutes.

Patients and controls will fill the Sexual Health Inventory for men (SHIM) questionnaire and answer the the Sexual Encounter Profile questions 1 and 2 (SEP 2 & SEP 3), and the global assessment question (GAQ) before and 4 weeks after treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03102762
Study type	Interventional
Source	Cairo University
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	January 3, 2017
Completion date	January 10, 2019

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05366504` - LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment	Phase 2/Phase 3
Recruiting	`NCT02573805` - the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males	N/A
Recruiting	`NCT02745808` - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes	Phase 1
Withdrawn	`NCT01967251` - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction	Phase 2
Withdrawn	`NCT02579148` - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes	Phase 1
Recruiting	`NCT02225548` - Sagene 2014 - Parkinson's Disease and Erectile Dysfunction	Phase 4
Completed	`NCT02587988` - Trial to Evaluate the Efficacy and Safety of HCP1302	Phase 3
Completed	`NCT02945462` - Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)	Phase 1
Completed	`NCT01937871` - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)	Phase 3
Completed	`NCT01698684` - Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction	Phase 4
Not yet recruiting	`NCT01321489` - A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies	Phase 3
Completed	`NCT01230541` - Effect of Udenafil on Spermatogenesis	Phase 1
Completed	`NCT02226237` - Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy	N/A
Terminated	`NCT01262833` - Pudendal Assessment in Erectile Dysfunction	N/A
Completed	`NCT01037218` - Treatment of Erectile Dysfunction II	Phase 3
Completed	`NCT01037244` - Treatment of Erectile Dysfunction I	Phase 3
Recruiting	`NCT00313898` - Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males	Phase 4
Completed	`NCT00663728` - Assessment of Duration of Erection With Vardenafil 10 mg	Phase 4
Completed	`NCT00667979` - Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse	Phase 4
Completed	`NCT00421083` - Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.